Patents by Inventor Lieping Chen

Lieping Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PD-L1 diabodies and the use thereof
    Patent number: 12263234
    Abstract: Provided are anti-PD-L1 diabodies, imaging agents, methods and kits for determination of the distribution and expression levels of PD-L1 in an individual having a disease or condition. Anti-PD-L1 diabody agents, and methods for treating diseases or disorders are also provided.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: April 1, 2025
    Assignee: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping Chen, Zhenguo Wen, Liqun Luo, Qianyong Liu
  • Anti-PD-1 antibodies, dosages and uses thereof
    Patent number: 12258407
    Abstract: Provided are anti-PD-1 antibodies or fragments thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 25, 2025
    Assignee: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping Chen, Liqun Luo
  • Compositions and methods for imaging
    Patent number: 12144875
    Abstract: Provided are methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents are also provided.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: November 19, 2024
    Assignee: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping Chen, Liqun Luo, Zhenguo Wen, Qianyong Liu
  • COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
    Publication number: 20240352120
    Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
    Type: Application
    Filed: February 15, 2024
    Publication date: October 24, 2024
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Lieping Chen, Scott E. Strome, Eugene D. Kwon, IV
  • ANTI-PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20240182579
    Abstract: Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.
    Type: Application
    Filed: October 24, 2023
    Publication date: June 6, 2024
    Inventors: Lieping CHEN, Liqun LUO
  • Compositions and uses thereof for treating disease or condition
    Patent number: 11987629
    Abstract: The present application provides methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents, and methods for treating diseases or disorders by administering anti-PD-L1 antibody agents are also provided.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: May 21, 2024
    Assignee: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping Chen, Liqun Luo
  • Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
    Patent number: 11939378
    Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 26, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Lieping Chen, Scott E. Strome, Eugene D. Kwon
  • B7-H5, a costimulatory polypeptide
    Patent number: 11760787
    Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 19, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Lieping Chen
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11560430
    Abstract: Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: January 24, 2023
    Assignee: Tayu Huaxia Biotech Medical Group Co., LTD
    Inventors: Lieping Chen, Liqun Luo
  • METHODS AND COMPOSITIONS FOR TREATING A DISEASE OR DISORDER
    Publication number: 20220235136
    Abstract: The present application provides agents that specifically inhibits the IGFBP7/CD93 signaling pathway, such as agents that specifically block the interaction between CD93 and IGFBF7, methods of using said agents and methods of identifying said agents.
    Type: Application
    Filed: March 25, 2022
    Publication date: July 28, 2022
    Applicants: YALE UNIVERSITY, The Regents of the University of Colorado, a body corporate
    Inventors: Yuwen ZHU, Lieping CHEN, Richard SCHULICK, Yi SUN
  • COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS
    Publication number: 20220168419
    Abstract: The present invention provides methods and compositions for treating a cancer, methods for increasing an immune response against a tumor, methods for treating an autoimmune disease, and methods for decreasing an inflammation response in a subject in need thereof by modulating the expression and/or activity of Siglec 15 and/or its binding ligands.
    Type: Application
    Filed: February 16, 2022
    Publication date: June 2, 2022
    Applicant: Yale University
    Inventors: Lieping Chen, Jun Wang, Jingwei Sun
  • ANTI-PD-L1 DIABODIES AND THE USE THEREOF
    Publication number: 20220088232
    Abstract: Provided are anti-PD-L1 diabodies, imaging agents, methods and kits for determination of the distribution and expression levels of PD-L1 in an individual having a disease or condition. Anti-PD-L1 diabody agents, and methods for treating diseases or disorders are also provided.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 24, 2022
    Applicant: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping CHEN, Zhenguo WEN, Liqun LUO, Qianyong LIU
  • Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
    Patent number: 11242387
    Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: February 8, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Lieping Chen, Scott E. Strome, Eugene D. Kwon
  • ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF IN CELL THERAPY
    Publication number: 20210395369
    Abstract: The present invention provides an anti-B7-H3 monoclonal antibody and use thereof in cell therapy. Specifically, the present invention provides an scFv, an antibody, and a specific CAR-T cell specifically targeting B7-H3. The present invention further provides an engineered immune cell capable of co-expressing a CAR targeting B7-H3 and a chimeric molecule or a secreted protein of PD-L1, the engineered immune cell having good tumor killing effects.
    Type: Application
    Filed: September 26, 2019
    Publication date: December 23, 2021
    Inventors: Lieping CHEN, Liqun LUO, Gangxiong HUANG
  • COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
    Publication number: 20210380690
    Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 9, 2021
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Lieping Chen, Scott E. Strome, Eugene D. Kwon
  • COMPOSITIONS AND METHODS FOR IMAGING
    Publication number: 20210309745
    Abstract: The present application provides methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents are also provided.
    Type: Application
    Filed: July 26, 2018
    Publication date: October 7, 2021
    Applicant: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping CHEN, Liqun LUO, Zhenguo WEN, Qianyong LIU
  • ANTI-PD-1 ANTIBODIES, DOSAGES AND USES THEREOF
    Publication number: 20210261665
    Abstract: Provided are anti-PD-1 antibodies or fragments thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.
    Type: Application
    Filed: July 19, 2019
    Publication date: August 26, 2021
    Applicant: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping CHEN, Liqun LUO
  • COMPOSITIONS AND METHODS FOR IMAGING
    Publication number: 20210213145
    Abstract: Provided are methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents are also provided.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 15, 2021
    Applicant: Tayu Huaxia Biotech Medical Group Co., Ltd.
    Inventors: Lieping CHEN, Liqun LUO, Zhenguo WEN, Qianyong LIU
  • COMPOSITIONS AND USES THEREOF FOR TREATING DISEASE OR CONDITION
    Publication number: 20210214444
    Abstract: The present application provides methods, imaging agents and kits for determination of the distribution and expression levels of an immune checkpoint ligand (such as PD-L1 or a PD-L1 like ligand) in an individual having a disease or condition. Anti-PD-L1 antibody agents, and methods for treating diseases or disorders by administering anti-PD-L1 antibody agents are also provided.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 15, 2021
    Applicant: Tayu Huaxia Biotech Medical Group Co., LTD
    Inventors: Lieping CHEN, Liqun LUO
  • Weed puller
    Patent number: D1074338
    Type: Grant
    Filed: May 10, 2024
    Date of Patent: May 13, 2025
    Assignee: Shenzhen Huazhi Trading Co., LTD
    Inventor: Lieping Chen